Nalaganje...
Bexarotene inhibits the viability of non-small cell lung cancer cells via slc10a2/PPARγ/PTEN/mTOR signaling pathway
BACKGROUND: Thirty to 40 % of non-small cell lung cancer (NSCLC) patients developed higher hypertriglyceridemia in the process of treatment with bexarotene. And bioinformatics studies discovered that the expression of slc10a2 was increased in high-grade hypertriglyceridemia patients. So, we will exp...
Shranjeno v:
| izdano v: | BMC Cancer |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BioMed Central
2018
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5896077/ https://ncbi.nlm.nih.gov/pubmed/29642873 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-4224-x |
| Oznake: |
Označite
Brez oznak, prvi označite!
|